Exploration of Novel Prognostic Markers in Grade 3 Neuroendocrine Neoplasia

Exploration of Novel Prognostic Markers in Grade 3 Neuroendocrine Neoplasia

Background: High-grade neuroendocrine tumours and carcinomas (NET/NECs) behave aggressively, typically presenting at an advanced stage. Prognosis is poor, with median survival between 5 and 34 months. The mainstay of treatment is palliative systemic therapy. However, therapy carries a risk of toxici...

Full description

Bibliographic Details
Main Authors: Rebecca Abdelmalak, Mark P. Lythgoe, Joanne Evans, Michael Flynn, Justin Waters, Andy Webb, David J. Pinato, Rohini Sharma
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Cancers
Subjects:
prognosis
neuroendocrine tumours
inflammation
survival
Online Access:https://www.mdpi.com/2072-6694/13/16/4232

Internet

https://www.mdpi.com/2072-6694/13/16/4232

Similar Items